1. Yang H., Bocchetta M., Kroczynska B., Elmishad A.G., Chen Y., Liu Z., Bubici C., Mossman B.T., Pass H.I., Testa J.R., Franzoso G., Carbone M. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis // Proc. Natl. Acad. Sci. USA. 2006. Vol. 103. No 27. P. 10397-10402.
2. Carbone M., Kratzke R.A., Testa J.R. Pathogenesis of mesothelioma // Semin. Oncol. 2002. Vol. 29. No 1. P. 2-17.
3. Ismail-Khan R., Robinson L.A., Williams Jr C.C., Garrett C.R., Be- pler G., Simon G.R. Malignant pleural mesothelioma: a comprehensive review // Cancer Control. 2006. Vol. 13. No 4. P. 255-263.
4. Testa J.R., Carbone M. Mesothelioma // Cancer research: an encyclopedic reference / Ed. by M. Schwab. Heidelberg: Springer-Verlay, 2002. P. 861-865.
5. Battifora H., McCaughey W.T.E. Tumor of serosal membranes // Atlas of tumor pathology / Ed. by J. Rosai, L.H. Sobin. Washington, 1995.
6. Boutin C., Schlesser M., Frenay C. et al. Malignant pleural mesothelioma // Europ. Respir. J. - 1998. - Vol. 12. - P. 972- 981
7. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. (WHO). Histological typing of lung and pleural tumour // Berlin, Springer - 1999 - ISBN -13: 978-3-540-65219-9
8. Hierholzer J. et al. MRI and CT in the Differential Diagnosis of Pleural Disease // Chest. - 2000. - Vol. 118. - P. 604- 609.
9. Schouwink J.H., Kool L.S., Rutgers E.J. et al. The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma // Ann. Thorac. Surg. - 2003. - Vol. 75. - P. 1715-1719.
10. Heelan R.T. et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging // AJR. Amer. J. Roent- genol. - 1999. - Vol. 172. - P.1039-1047.
11. Hierholzer J. et al. MRI and CT in the Differential Diagnosis of Pleural Disease // Chest. - 2000. - Vol. 118. - P. 604- 609.
12. Maziak D.E., Gagliardi A., Haynes A.E. et al. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary // Lung. Cancer. - 2005. -Vol. 48 (2). - P. 157- 169.
13. ORourke N, Garcia JC, Paul J et al. A randomized controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007; 84: 18-22.
14. Castagneto B, Bota M, Aitini E et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma. Ann Oncol 2008; 19: 370373.
15. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
16. Nakas A, Ucar M, Edwards JG, Waller DA. The role of video-assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2008; 33: 83-88.
17. Vorobiof D.A., Mafafo K. Malignant pleural mesothelioma: medical treatment update // Clin. Lung Cancer. 2009. Vol. 10. No 2. P. 112-117.
18. Robinson B.W., Lake R.A. Advances in Malignant Mesothelioma // New. Engl. J. Med. -2005. - Vol. 353. - P. 1591-603.
19. Nico van Zandwijk Guidelines for the diagnosis and treatment of malignant pleural mesothelioma / J Thorac Dis. 2013 Dec; 5(6): E254-E307. // Nico van Zandwijk, Christopher Clarke, Douglas Henderson, A. William Musk, Kwun Fong, Anna Nowak, Robert Loneragan, Brian McCaughan, Michael Boyer, Malcolm Feigen, David Currow, Penelope Schofield, Beth Ivimey Nick Pavlakis, Jocelyn McLean, Henry Marshall, Steven Leong, Victoria Keena, and Andrew Penman